Comparison of Multi-parametric and Bi-parametric Magnetic Resonance Imaging in Men With Suspicion of Prostate Cancer

Prostatic Neoplasm Clinical Trial

Official title:

Cost-efficacy of a Preliminary Diagnostic Program Using Bi-parametric Magnetic Resonance Imaging in Men With Suspicion of Prostate Cancer and no Previous Prostate Biopsy: a Prospective Randomized Clinical Study Comparing Multiparametric and Bi-parametric Magnetic Resonance Imaging Results

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03693703
• Other study ID #: bpMRscr16
• Status: Completed
• Phase: N/A
• Start date: April 18, 2018
• Est. completion date: March 31, 2020

Study information

• Verified date: August 2020
• Source: Fondazione del Piemonte per l'Oncologia
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To compare the detection rate of biparametric (bp) magnetic resonance imaging (MRI) for clinically significant prostate cancer (PCa) with that of multiparametric (mp)-MRI, in biopsy-naïve patients. Today, bp-MRI is not the standard diagnostic procedure, however preliminary studies showed its non-inferiority with respect to mp-MRI. Its implementation on a wide scale could significantly reduce examination costs (no iv contrast agent and no endorectal coil), and study time.

Secondary objectives will be:

• to assess specificity of a blood test based on microRNA (miR) score in biopsy-naïve patients, using pathological assessment after MR-guided biopsy as reference standard. If specificity of the miR score is higher than that of PSA, then fewer patients will undergo unnecessary MRI, thus increasing the efficiency of the diagnostic pipeline for PCa;

• to develop a clinical decision support system (CDSS) based on MRI and circulating miR evaluation, to stratify patients according to their risk of PCa progression, using pathological assessment after prostatectomy as reference standard. Patients will be stratified into two classes of risk: i) low-risk PCa, in which patients may benefit from a conservative approach (i.e. active surveillance), and ii) medium/high-risk PCa in which patients should undergo radical treatment (i.e. surgery or radiation therapy).

Description:

The trial is a prospective, randomized, two-arms study with a 2:1 ratio. Subjects meeting the inclusion criteria will be randomized either into the bp-MRI group (arm A), or the mp-MRI one (arm B). All subjects will perform blood sampling in EDTA tubes before undergoing imaging session. Plasma will be isolated within 1 hour from sampling, with a double round centrifugation, aliquoted and stored at -80°C before undergoing miR analysis.

MRI will be performed with a 1.5 T using axial T2w and diffusion-weighted imaging for subjects in arm A with no endorectal coil and no intravenous contrast agent. Men randomized in arm B will undergo MRI with T2w in the three acquisition planes, diffusion-weighted and dynamic contrast-enhanced imaging usign endorectal coil.

Random biopsy will be performed in subjects with no suspicious regions for PCa found on MRI. Men with suspicious regions on MRI will be invited to a targeted or in-bore biopsy.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 391
• Est. completion date: March 31, 2020
• Est. primary completion date: March 31, 2020
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• age <= 75 years

• PSA <= 15 ng/ml

• no previous prostate biopsy

• negative digital rectal examination

• signed infomed conset

Exclusion Criteria:

• known prostate cancer diagnosis

• previous prostate biopsy or surgery

• contraindication to MRI

• non-cooperative subjects

Related Conditions & MeSH terms

• Prostatic Neoplasm
• Prostatic Neoplasms

Intervention

Diagnostic Test:
• bi-parametric MRI
Axial T2-weighted and diffusion-weighted imaging with no endorectal coil nor intravenous contrast agent administration
• multi-parametric MRI
T2-weighted imaging in the three planes, diffusion-weighted and dynamic contrast-enhanced imaging using endorectal coil and intravenous contrast agent administration

Locations

Country	Name	City	State
Italy	Fondazione del Piemonte per l'Oncologia - Candiolo Cancer Institute	Candiolo	Turin

Sponsors (1)

Lead Sponsor	Collaborator
Fondazione del Piemonte per l'Oncologia

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Detection rate of bi-parametric MRI, and of mp-MRI in men at risk for PCa and with no previous prostate biopsy	Sensitivity, specificity, PPV and NPV will be measured	3 months
Secondary	Dimension of lesions identified at bp-MRI/mp-MRI;	Mean lesion dimension will be assessed in each study arm	2 weeks
Secondary	The proportion of clinically significant PCa identified at bp-MRI;	The number of clinically significant PCa over the total number of PCa detected at bp-MRI will be measured	2 weeks
Secondary	Positive predictive value of miR test alone and in combination with PSA blood test in identifying histologically confirmed PCa patients		3 months